Current Oncology Reports

, Volume 11, Issue 2, pp 143–150 | Cite as

Quality of life of oropharyngeal cancer patients treated with brachytherapy

  • David N. Teguh
  • Peter C. Levendag
  • Inger-Karine Kolkman-Deurloo
  • Peter van Rooij
  • Paul I. M. Schmitz
Article

Abstract

Brachytherapy (BT) is a highly conformal (accurate clinical target volume delineation, no planning target volume margin) radiotherapy technique; the radioactive source, guided by afterloading catheters, is implanted into the heart of the tumor. The localized high dose of radiation enables high tumor control rates and, because of rapid dose fall-off, sparing of the adjacent normal tissues. At the Erasmus Medical Center, excellent results were observed: 5-year local regional control of 84%, 5-year disease-free survival of 59%, and 5-year overall survival of 64%. Therefore, in the case of moderately sized tumors, for well-trained, skillful physicians, BT is the therapy of choice (if technically feasible). However, side effects are not totally negligible, partly because of the cumulative dose of BT and the first series of 46/2 Gy. However, patients treated with BT still have a better swallowing-related quality of life, which might improve further if summation of BT and the first series of 46/2 Gy, as well as autocontouring of the neck levels, are realized. So far, there is no significant relationship between the quality index of the BT implants and local control/overall survival and/or quality of life.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Popovtzer A, Eisbruch A. Advances in radiation therapy of head and neck cancer. Expert Rev Anticancer Ther 2008, 8:633–644.PubMedCrossRefGoogle Scholar
  2. 2.
    Logemann JA: Update on clinical trials in dysphagia. Dysphagia 2006, 21:116–120.PubMedCrossRefGoogle Scholar
  3. 3.
    Dornfeld K, Simmons JR, Karnell L, et al.: Radiation doses to structures within and adjacent to the larynx are correlated with long-term diet- and speech-related quality of life. Int J Radiat Oncol Biol Phys 2007, 68:750–757.PubMedGoogle Scholar
  4. 4.
    Feng FY, Lyden TH, Kim HM, et al.: IMRT aimed at reducing dysphagia: early dose-volume-effect relationships for swallowing structures. Int J Radiat Oncol Biol Phys 2006, 66:S44–S45.Google Scholar
  5. 5.
    Jensen K, Lambertsen K, Grau C: Late swallowing dysfunction and dysphagia after radiotherapy for pharynx cancer: frequency, intensity and correlation with dose and volume parameters. Radiother Oncol 2007, 85:74–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Levendag PC, Teguh DN, Voet P, et al.: Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007, 85:64–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Teguh DN, Levendag PC, Noever I, et al.: Treatment techniques and site considerations regarding dysphagia-related quality of life in cancer of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 2008, 72:1119–1127.PubMedGoogle Scholar
  8. 8.
    Goffinet DR, Fee WE Jr, Wells J, et al.: 192Ir pharyngoepiglottic fold interstitial implants. The key to successful treatment of base tongue carcinoma by radiation therapy. Cancer 1985, 55:941–948.PubMedCrossRefGoogle Scholar
  9. 9.
    Crook J, Mazeron JJ, Marinello G: Combined external and interstitial implantation for T1 and T2 epidermoid carcinoma of base of tongue: the Creteil experience. Int J Radiat Oncol Biol Phys 1988, 15:105–114.PubMedGoogle Scholar
  10. 10.
    Esche BA, Haie CM, Gerbaulet AP, et al.: Interstitial and external radiotherapy in carcinoma of the soft palate and uvula. Int J Radiat Oncol Biol Phys 1988, 15:619–625.PubMedGoogle Scholar
  11. 11.
    Foote RL, Parsons JT, Mendenhall WM: Is interstitial implantation essential for successful treatment of base of tongue carcinoma? Int J Radiat Oncol Bol Phys 1990, 18:1293–1298.Google Scholar
  12. 12.
    Gerbaulet A, Poetter R, Mazeron JJ: The GEC ESTRO Handbook of Brachytherapy. Brussels, Belgium: European Society for Therapeutic Radiology and Oncology; 2002.Google Scholar
  13. 13.
    Horwitz EM, Frazier AJ, Martinez AA: Excellent functional outcome in patients with squamous cell carcinoma of the base of the tongue treated with external irradiation and interstitial iodine 125 boost. Cancer 1996, 78:948–957.PubMedCrossRefGoogle Scholar
  14. 14.
    Mazeron JJ, Marinello G, Crook J: Definitive radiation treatment for early stage carcinoma of the soft palate and uvula: the indication for iridium 192 implantation. Int J Radiat Oncol Biol Phys 1987, 13:1829–1837.PubMedGoogle Scholar
  15. 15.
    Pernot M, Hoffstetter S, Pfeiffert D, et al.: Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otolaryngol Head Neck Surg 1996, 115:519–526.PubMedCrossRefGoogle Scholar
  16. 16.
    Mazeron JJ, Crook J, Martin M, et al.: Iridium 192 implantation of squamous cell carcinomas of the oropharynx. Am J Otolaryngol 1989, 10:317–321.PubMedCrossRefGoogle Scholar
  17. 17.
    Pernot M, Hoffstetter S, Peiffert D, et al.: Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otolaryngol Head Neck Surg 1996, 115:519–526.PubMedCrossRefGoogle Scholar
  18. 18.
    Levendag P, Nijdam W, Noever I, et al.: Brachytherapy versus surgery in carcinoma of tonsillar fossa and/or soft palate: late adverse sequelae and performance status: can we be more selective and obtain better tissue sparing? Int J Radiat Oncol Biol Phys 2004, 59:713–724.PubMedGoogle Scholar
  19. 19.
    Levendag PC, Schmitz PI, Jansen PP, et al.: Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: first clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate. Int J Radiat Oncol Biol Phys 1997, 38:497–506.PubMedGoogle Scholar
  20. 20.
    Vikram B, Hilaris BS: A non-looping afterloading technique for interstitial implants of the base of the tongue. Int J Radiat Oncol Biol Phys 1981, 7:419–422.PubMedGoogle Scholar
  21. 21.
    Vikram B, Strong E, Shah J, et al.: A non-looping afterloading technique for base of tongue implants: results in the first 20 patients. Int J Radiat Oncol Biol Phys 1985, 11:1853–1855.PubMedGoogle Scholar
  22. 22.
    Harrison LB, Lee HJ, Pfister DG, et al.: Long term results of primary radiotherapy with/without neck dissection for squamous cell cancer of the base of tongue. Head Neck 1998, 20:668–673.PubMedCrossRefGoogle Scholar
  23. 23.
    Housset M, Baillet F, Dessard-Diana B, et al.: A retrospective study of three treatment techniques for T1–T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. Int J Radiat Oncol Biol Phys 1987, 13:511–516.PubMedGoogle Scholar
  24. 24.
    Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355:949–955.PubMedGoogle Scholar
  25. 25.
    Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet 2008, 371:1695–1709.PubMedCrossRefGoogle Scholar
  26. 26.
    Piccirillo JF, Vlahiotis A: Comorbidity in patients with cancer of the head and neck: prevalence and impact on treatment and prognosis. Curr Oncol Rep 2006, 8:123–129.PubMedCrossRefGoogle Scholar
  27. 27.
    Harrison LB, Zelefsky MJ, Pfister DG, et al.: Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 1997, 19:169–175.PubMedCrossRefGoogle Scholar
  28. 28.
    Babin E, Sigston E, Hitier M, et al.: Quality of life in head and neck cancers patients: predictive factors, functional and psychosocial outcome. Eur Arch Otorhinolaryngol 2008, 265:265–270.PubMedCrossRefGoogle Scholar
  29. 29.
    Pourel N, Peiffert D, Lartigau E, et al.: Quality of life in long-term survivors of oropharynx carcinoma. Int J Radiat Oncol Biol Phys 2002, 54:742–751.PubMedGoogle Scholar
  30. 30.
    Petruson K, Mercke C, Lundberg LM, et al.: Longitudinal evaluation of patients with cancer in the oral tongue, tonsils, or base of tongue-does interstitial radiation dose affect quality of life? Brachytherapy 2005, 4:271–277.PubMedCrossRefGoogle Scholar
  31. 31.
    Hammerlid E, Mercke C, Sullivan M, Westin T: A prospective quality of life study of patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without brachytherapy. Oral Oncol 1997, 33:189–196.PubMedCrossRefGoogle Scholar
  32. 32.
    Nijdam W, Levendag P, Noever I, et al.: Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol 2005, 77:65–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Poulsen MG, Riddle B, Keller J, et al.: Predictors of acute grade 4 swallowing toxicity in patients with stages III and IV squamous carcinoma of the head and neck treated with radiotherapy alone. Radiother Oncol 2008, 87:253–259.PubMedCrossRefGoogle Scholar
  34. 34.
    Mangar S, Slevin N, Mais K, Sykes A: Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer: a retrospective review. Radiother Oncol 2006, 78:152–158.PubMedCrossRefGoogle Scholar
  35. 35.
    Caudell JJ, Schaner PE, Meredith RF, et al.: Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2008 Jul 15 [Epub ahead of print].Google Scholar
  36. 36.
    Feng FY, Kim HM, Lyden TH, et al.: Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 2007, 68:1289–1298.PubMedGoogle Scholar
  37. 37.
    Jensen K, Lambertsen K, Grau C: Dysphagia, aspiration and speech problems after radiotherapy for pharyngeal cancer correlate with dose-volume parameters of the supraglottic region. Radiother Oncol 2006, 81:S167.Google Scholar
  38. 38.
    Greene FL, Page DL, Fleming ID, et al.: AJCC Cancer Staging Manual, edn 6. New York: Springer; 2002.Google Scholar
  39. 39.
    van de Pol M, Levendag PC, de Bree RR, et al.: Radical radiotherapy compared with surgery for advanced squamous cell carcinoma of the base of tongue. Brachytherapy 2004, 3:78–86.PubMedCrossRefGoogle Scholar
  40. 40.
    Bjordal K, de Graeff A, Fayers PM, et al.: A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H& N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000, 36:1796–1807.PubMedCrossRefGoogle Scholar
  41. 41.
    List MA, D’Antonio LL, Cella DF, et al.: The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy head and neck scale—a study of utility and validity. Cancer 1996, 77:2294–2301.PubMedCrossRefGoogle Scholar
  42. 42.
    Chen AY, Frankowski R, Bishop-Leone J, et al.: The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg 2001, 127:870–876.PubMedGoogle Scholar
  43. 43.
    Thomadsen B, Houdek P, van der Laarse R, et al.: Treatment planning and optimization. In HDR Brachytherapy: A Textbook. Edited by Nag S. Armonk, NY: Futura; 1994:79–145.Google Scholar
  44. 44.
    Saw CB, Suntharalingam N: Quantitative assessment of interstitial implants. Int J Radiat Oncol Biol Phys 1991, 20:135–139.PubMedGoogle Scholar
  45. 45.
    Anderson LL: A “natural” volume-dose histogram for brachytherapy. Med Phys 1986, 13:898–903.PubMedCrossRefGoogle Scholar
  46. 46.
    Kolkman-Deurloo IK, Visser AG, Niel CG, et al.: Optimization of interstitial volume implants. Radiother Oncol 1994, 31:229–239.PubMedCrossRefGoogle Scholar
  47. 47.
    Das R: ICRU 58 (Dose and Volume Specification for Reporting Interstitial Therapy), by International Commission on Radiation Units and Measurements. Med Phys 1998, 25:1225.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  • David N. Teguh
  • Peter C. Levendag
    • 1
  • Inger-Karine Kolkman-Deurloo
  • Peter van Rooij
  • Paul I. M. Schmitz
  1. 1.Erasmus University Medical Center-Daniel den Hoed Cancer CenterRotterdamThe Netherlands

Personalised recommendations